Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will host a virtual investor and analyst event on December 8, 2025 at 12:30 PM ET / 9:30 AM PT to discuss data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The presentation covers results scheduled for the 67th ASH Annual Meeting. Management and lead investigators will participate. A live webcast and replay will be available on the company website under Investors > Events and Presentations.

News Market Reaction – KURA

+7.55%

21 alerts

+7.55% Session close to close

+4.1% Peak in 20 min

$1.05B Market Cap

0.1x Rel. Volume

In the Dec 3 session, KURA gained 7.55%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +7.5% in the session following this news. A strong positive reaction aligns with the pattern seen when Kura highlighted its ASH-related investor event, which previously saw a 7.55% gain. However, history also showed negative moves after favorable commercialization and data updates, suggesting enthusiasm sometimes faded quickly. Investors monitoring such a surge might have weighed ongoing ziftomenib news flow, insider sell-to-cover activity, and overall biotech volatility when assessing how durable the strength could be.

Key Figures

Event date: December 8, 2025 Event time ET: 12:30 PM ET Event time PT: 9:30 AM PT +1 more

4 metrics

Event date December 8, 2025 Scheduled virtual analyst and investor event

Event time ET 12:30 PM ET Start time for virtual investor event

Event time PT 9:30 AM PT Start time for virtual investor event

ASH meeting number 67th 67th American Society of Hematology Annual Meeting

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 08	ASH combo data	Positive	-2.6%	Detailed ASH 2025 data on KOMZIFTI triplet in AML cohorts.
Dec 03	Investor event notice	Positive	+7.5%	Announcement of Dec 8 virtual investor/analyst event on ASH data.
Dec 02	First U.S. sale	Positive	-2.7%	First U.S. KOMZIFTI sale triggering $135M milestone payment.
Nov 25	NCCN guideline add	Positive	+3.4%	KOMZIFTI added as Category 2A AML option in NCCN guidelines.
Nov 13	FDA approval	Positive	+0.0%	FDA approval of KOMZIFTI for R/R NPM1-mutated AML patients.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent major ziftomenib milestones have mostly seen positive or flat next-day reactions, but some commercialization and data updates drew negative moves, highlighting occasional divergence even on favorable news.

Recent Company History

Over the last month, Kura reported several key milestones for KOMZIFTI (ziftomenib), including full FDA approval on Nov 13, subsequent inclusion in NCCN AML guidelines on Nov 25, and the first U.S. commercial sale with a $135 million milestone on Dec 2. Additional ASH 2025 triplet-combination data with venetoclax and azacitidine were highlighted on Dec 8. Today’s investor event announcement on Dec 3 fits into this cluster of regulatory, commercial, and clinical catalysts around ziftomenib.

Key Terms

acute myeloid leukemia, relapsed/refractory

2 terms

acute myeloid leukemia medical

"triplet combination of ziftomenib (KOMZIFTI®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled"

A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.

relapsed/refractory medical

"with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled"

Relapsed/refractory describes a disease, usually cancer, that has returned after treatment (relapsed) or that did not respond to initial therapy (refractory). For investors this signals a high medical need and a defined patient group for new treatments — like a market of cars that won’t start with a standard key — which can affect drug development priorities, trial designs, potential pricing and commercial opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Event Scheduled for December 8, 2025 at 12:30 PM ET

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual analyst and investor event on Monday, December 8, 2025, at 12:30 PM ET / 9:30 AM PT, to discuss data on the triplet combination of ziftomenib (KOMZIFTI^®) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia scheduled for presentation at the 67th American Society of Hematology (ASH) Annual Meeting.

The virtual event will feature members of the management team alongside lead investigators. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When is the Kura Oncology (KURA) virtual investor event to discuss ASH 2025 data?

The event is scheduled for December 8, 2025 at 12:30 PM ET / 9:30 AM PT.

What data will Kura Oncology (KURA) discuss at the December 8, 2025 webcast?

Data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory AML.

How can investors watch the Kura Oncology (KURA) ASH 2025 event webcast?

The live webcast and replay will be available on Kura Oncology’s website under Investors > Events and Presentations.

Who will present at the Kura Oncology (KURA) virtual analyst and investor event on December 8, 2025?

The presentation will feature members of management alongside the lead investigators for the ASH 2025 data.

What topic will Kura Oncology (KURA) cover from the 67th ASH Annual Meeting on December 8, 2025?

The company will discuss ASH 2025 results for the ziftomenib, venetoclax, and azacitidine triplet regimen in AML.